Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) |
| 24 Feb 2022 |
| Orion’s collaboration partner Bayer upgrades estimate on Nubeqa®’s peak sales potential | 17 Feb 2022 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 17 Feb 2022 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 11 Feb 2022 |
| Orion Group Financial Statement Release for 2021 | 10 Feb 2022 |